New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
A Single Injection of Amniotic Suspension Allograft is Safe and Effective for Treatment of Mild to Moderate Hip Osteoarthritis: A Prospective Study.
A Single Injection of Amniotic Suspension Allograft is Safe and Effective for Treatment of Mild to Moderate Hip Osteoarthritis: A Prospective Study. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association Meadows, M., Elisman, K., Nho, S., Mowry, K., Safran, M. 2021Abstract
PURPOSE: The purpose of our study was to examine the effects of a commercially available amniotic suspension allograft (ASA) (ReNuTM, Organogenesis, Canton, MA) in a patient population with moderate osteoarthritis of the hip.METHODS: Ten patients with symptomatic hip osteoarthritis, defined as Tonnis grade 1 or 2 on radiographic examination, were prospectively enrolled. Each patient received a single image-guided injection of ASA into the hip joint. Patient-reported outcomes measures, including the iHOT12, mHHS, and SANE scores were recorded at baseline, 6 months, and 12 months post-injection. A linear regression model was performed to detect differences in outcome scores from baseline.RESULTS: Nine patients had complete 12-month data available for analysis. One patient failed treatment and underwent arthroplasty at 2 months post-injection. The cohort includes 5 males and 4 females, ages 47-67. iHOT scores demonstrated a significant improvement between baseline and 12 months (p = 0.02). SANE scores demonstrated a significant difference between baseline and 6 months (p < 0.01), as well as between baseline and 12 months (p < 0.01). mHHS scores demonstrated a significant difference between baseline and 6 months (p = 0.02) and between baseline and 12 months (p = 0.01). There were no major adverse events in the course of the study period.CONCLUSION: This study demonstrates promising results for relief of pain and improvement in patient-reported outcomes with intra-articular ASA in patients with moderate osteoarthritis of the hip for up to one year, though the exact mechanism of action remains unknown.
View details for DOI 10.1016/j.arthro.2021.04.034
View details for PubMedID 33940131